StocksMedium•12 November 2026•
1 min read
X-energy and Fennec Pharmaceuticals Report Strong Q3 2026 Revenue Growth
Key Facts
1X-energy reported Q3 revenues and grant income of $66.3 million, up from $30.4 million in the prior year period.
2Fennec Pharmaceuticals reported net product sales of $19.4 million, representing a 56% year-over-year increase.
3X-energy selected Fluor Corporation to advance nuclear engineering and design for its second Xe-100 project.
X-energy reported Q3 2026 revenues and grant income of $66.3 million, a significant increase from $30.4 million in the prior year period. According to GlobeNewswire, the company selected Fluor Corporation to advance nuclear engineering and design for its second Xe-100 project. Separately, Fennec Pharmaceuticals reported net product sales of $19.4 million, representing a 56% year-over-year increase.
XE shares closed at $10.94 on November 11, 2026, as the company maintained a total liquidity position of $1,805.5 million as of September 30, 2026. In the engineering sector, FLR closed at $50.62 on November 11, 2026. Meanwhile, FENC closed at $10.64 on the same date, reflecting its continued commercial growth in product sales.